We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-4.66%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$160M
AUM Growth
+$25M
Cap. Flow
+$50.2M
Cap. Flow %
31.35%
Top 10 Hldgs %
99.66%
Holding
12
New
1
Increased
–
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
BCAX
Bicara Therapeutics
BCAX
+$56.2M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.45M
2
NUVB icon
Nuvation Bio
NUVB
+$621K
3
ALMS
Alumis Inc
ALMS
+$24

Sector Composition

Rank Sector Weight
1 Healthcare 99.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCAX
1
Bicara Therapeutics
BCAX
$1.78B
$56.2M 35.09%
+2,204,650
New +$56.2M
NUVB icon
2
Nuvation Bio
NUVB
$2.24B
$29.9M 18.71%
13,072,340
-203,544
-2% -$621K
REPL icon
3
Replimune Group
REPL
$814M
$27M 16.86%
2,461,319
– –
LXEO icon
4
Lexeo Therapeutics
LXEO
$366M
$21.3M 13.31%
2,355,904
– –
ENGN icon
5
enGene Therapeutics
ENGN
$122M
$7.1M 4.44%
1,076,357
– –
ALMS
6
Alumis Inc
ALMS
$3.57B
$6.98M 4.36%
653,223
-2
-0% -$24
IMA
7
ImageneBio Inc
IMA
$63.1M
$3.89M 2.43%
187,427
– –
SANA icon
8
Sana Biotechnology
SANA
$885M
$3.51M 2.19%
843,750
– –
IMUX icon
9
Immunic
IMUX
$182M
$2.95M 1.84%
178,816
– –
ENGNW icon
10
enGene Therapeutics Warrants
ENGNW
$3.75M
$675K 0.42%
321,502
– –
SYRS
11
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$540K 0.34%
251,270
– –
MORF
12
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-159,846
Closed -$5.45M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q3 2024 Portfolio in Review

As of Q3 2024, Omega Fund Management held 12 positions worth $160M, up 19% from $135M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Omega Fund Management deployed $50.2M of net new capital in Q3 2024, opening 1 new position. Its largest new stake was Bicara Therapeutics: 2,204,650 shares worth $56.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Nuvation Bio, an estimated $621K trimmed.

  • Omega Fund Management's largest Q3 2024 buy was Bicara Therapeutics: 2,204,650 shares worth $56.2M.
  • Omega Fund Management's biggest Q3 2024 reduction was Nuvation Bio, cutting an estimated $621K.
  • Omega Fund Management fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $5.45M.
  • Omega Fund Management's ten largest holdings make up 100% of its $160M portfolio in Q3 2024.
  • Omega Fund Management opened 1 new position and closed 1 in Q3 2024.
  • Omega Fund Management's portfolio value rose 19% quarter-over-quarter to $160M.

Based on Omega Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.